5.13
-0.01 (-0.19%)
| Penutupan Terdahulu | 5.14 |
| Buka | 5.15 |
| Jumlah Dagangan | 3,298,016 |
| Purata Dagangan (3B) | 4,074,223 |
| Modal Pasaran | 1,786,276,224 |
| Harga / Jualan (P/S) | 12.08 |
| Harga / Buku (P/B) | 5.36 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,913.23% |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.72% |
| Nisbah Semasa (MRQ) | 9.01 |
| Aliran Tunai Operasi (OCF TTM) | -157.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.76 M |
| Pulangan Atas Aset (ROA TTM) | -23.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -119.66% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nuvation Bio Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 1.10 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.14% |
| % Dimiliki oleh Institusi | 62.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2026 | 25,954,439 |
| Omega Fund Management, Llc | 31 Mar 2026 | 8,081,089 |
| Laurion Capital Management Lp | 31 Mar 2026 | 7,822,638 |
| Duquesne Family Office Llc | 31 Mar 2026 | 4,539,800 |
| Redmile Group, Llc | 31 Mar 2026 | 3,153,256 |
| Tang Capital Management Llc | 31 Mar 2026 | 3,149,557 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MASHAL ROBERT | 4.93 | - | 25,000 | 123,250 |
| Jumlah Keseluruhan Kuantiti Bersih | 25,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 123,250 | |||
| Purata Pembelian Keseluruhan ($) | 4.93 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MASHAL ROBERT | Pengarah | 09 Jun 2026 | Beli (+) | 25,000 | 4.93 | 123,250 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |